Monday, August 21, 2017 11:11:01 PM
Given the claim in today's PR that 11 patients out of a likely 11-13 or so had no detectable viral load after 25 weeks of therapy, the chances of the PE being outstanding seem pretty high. I suspect the PE info will be released as quickly as they can and may be well before the 10/17 meeting with the FDA. And there will be an offering immediately following that.
The big question is how big an offering will it be? I don't have a good answer for that and could see it being in the $15 million range to much larger (a scenario where they throw the old shareholders under the bus in order to once and for all get the balance sheet squared away so they can stop the constant fund raisings that have become so toxic to the share price).
I suppose the PE data could not be outstanding and the 25 week data great and that could add a whole new dimension of weird to the story. If they try to raise money before the PE data is available, then I might believe this as a possibility.
Can someone tell me what the procedure for the trial is again? When the drug or the placebo is given on day one, the patient already on a failing regimen - correct? So, the benefit from PRO 140 should be quite obvious at 7 days as well as at 25 weeks.
The big question is how big an offering will it be? I don't have a good answer for that and could see it being in the $15 million range to much larger (a scenario where they throw the old shareholders under the bus in order to once and for all get the balance sheet squared away so they can stop the constant fund raisings that have become so toxic to the share price).
I suppose the PE data could not be outstanding and the 25 week data great and that could add a whole new dimension of weird to the story. If they try to raise money before the PE data is available, then I might believe this as a possibility.
Can someone tell me what the procedure for the trial is again? When the drug or the placebo is given on day one, the patient already on a failing regimen - correct? So, the benefit from PRO 140 should be quite obvious at 7 days as well as at 25 weeks.
Recent CYDY News
- CytoDyn Completes Enrollment in Phase 2 Metastatic Colorectal Cancer Study • GlobeNewswire Inc. • 04/21/2026 08:10:00 PM
- CytoDyn Presents New Leronlimab Data in Metastatic Triple-Negative Breast Cancer at AACR Annual Meeting 2026 • GlobeNewswire Inc. • 04/20/2026 12:30:00 PM
- CytoDyn to Present at the AACR Annual Meeting 2026 • GlobeNewswire Inc. • 04/14/2026 12:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 04/08/2026 09:15:18 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 04/08/2026 12:30:28 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 03/25/2026 09:16:10 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:24:23 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:23:14 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:22:42 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:21:33 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:20:57 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:20:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/24/2026 09:15:24 PM
- CytoDyn Presents at AACR Special Conference in Cancer Research: Brain Cancer • GlobeNewswire Inc. • 03/24/2026 12:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 03/09/2026 09:15:18 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/05/2026 01:35:02 PM
- CytoDyn Closes $17.5 Million Financing to Fund Continued Development of Leronlimab • GlobeNewswire Inc. • 03/05/2026 01:30:00 PM
- CytoDyn Presents Novel CCR5 Inhibition Mechanisms and Long-Term Survival Signals for Leronlimab in Metastatic Breast Cancer at AACR Immuno-Oncology Conference • GlobeNewswire Inc. • 02/20/2026 01:30:00 PM
- CytoDyn Announces Funding and Initiation of Expanded Access Program for Patients with Triple-negative Breast Cancer • GlobeNewswire Inc. • 01/27/2026 01:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 01/09/2026 10:15:22 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 01/09/2026 01:30:45 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 12/22/2025 10:15:23 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 12/17/2025 05:15:14 AM
- December 2025 Letter to Shareholders • GlobeNewswire Inc. • 12/16/2025 01:30:00 PM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 12/10/2025 10:16:32 PM
